IGT with fasting hyperglycemia is more strongly associated with microalbuminuria than IGT without fasting hyperglycemia

Diabetes Research and Clinical Practice

Volumn 64, Issue 3, 2004, Pages 213-219

  Suzuki, Haruhiko ^a   Fukushima, Mitsuo ^a   Usami, Masaru ^b   Ikeda, Masaki ^b   Taniguchi, Ataru ^c   Nakai, Yoshikatsu ^a   Matsuura, Toshifumi ^d   Yasuda, Koichiro ^a   Hosokawa, Masaya ^a   Seino, Yutaka ^a   Yamada, Yuichiro ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Ikeda Municipal Hospital   (Japan)

^c KANSAI DENRYOKU HOSPITAL   (Japan)

^d Kansai Health Management Center   (Japan)

Author keywords

Fasting hyperglycemia; Impaired glucose tolerance; Insulin resistance; Microalbuminuria; Type 2 diabetes

Indexed keywords

ALBUMIN; CREATININE; GLUCOSE;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIET RESTRICTION; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PROTEIN URINE LEVEL; REGRESSION ANALYSIS;

ADULT; AGED; ALBUMINURIA; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; CHOLESTEROL, HDL; CREATININE; CROSS-SECTIONAL STUDIES; FASTING; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; JAPAN; MALE; MIDDLE AGED; REGRESSION ANALYSIS; TRIGLYCERIDES;

EID: 2342535127     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2003.11.008     Document Type: Article

References (32)

1. Graves M., Malia R.G., Goodfellow K., et al. EURODIAB IDDM Complication Study Group: Fibrinogen and van Willebrand factor in IDDM: relationships to lipid vascular riskfactors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM complications study. Diabetolgia. 40:1997;698-705
2. Stehouwer C.D., Nauta J.J.P., Zeldenrust G.C., Hackeng W.H.L., Donker A.J.M., Den Ottolander G.J.H. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 340:1992;319-323
3. Seligman B.G.S., Biolo A., Planczyk C.A., Gross J.L., Clausell N. Increased plasma levels of endothelin 1 and van Willebrand factor in patients with Type 2 diabetes and dyslipidemia. Diabetes Care. 23:2000;1395-1400
4. Yudkin J.S., Forrest R.D., Jackson C.A. Microalbuminuria as predictor of vascular disease in non-diabetic subjects: Islington Diabetes Study. Lancet. ii:1988;530-533
5. Mattock M.B., Morrish N.J., Viberti G.C., Keen H., Fitzgerald A.P., Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes. 41:1992;736-741
6. Mattock M.B., Barnes D.J., Vibetrti B., et al. Microalbuminuria and coronary heart disease in NIDDM: An Incidence Study. Diabetes. 47:1998;1786-1792
7. Savage S., Estacio R.O., Jeffers B., Schrier R.W. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care. 19:1996;1243-1248
8. Nelson R.G., Runzelman C.L., Pettitt D.J., Saad M.F., Bennett P.H., Knowler W.C. Albuminuria in Type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in Pima Indians. Diabetologia. 32:1989;870-876
9. Haffner S.M., Gonzales C., Valdes R.A., et al. Is microalbuminuria part of the prediabetic state? The Mexico City Diabetes Study. Diabetologia. 36:1993;1002-1006
10. Mykkanen L., Zaccaro D.J., Wagenknecht L.E., Robbins D.C., Gaberiel M., Haffner S.M. Microalbuninuria is associated with insulin resistance in nondiabetic subjects: The Insulin Resistance Atherosclerosis Study. Diabetes. 47:1998;793-800
11. Rowley K.G., Iser D.M., Best J.D., O'Dea K., Leonard D., McDermot R. Albuminuria in Australian aboriginal people: prevalence and association with components of the metabolic syndrome. Diabetologia. 43:2000;1397-1403
12. Alberti K.G., Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet. Med. 15:1998;539-553
13. Tripathy D., Carlsson M., Almgren P., et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lesson from the Botnia Study. Diabetes. 49:2000;975-980
14. Suzuki H., Fukushima M., Usami M., et al. Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia. Diabetes Care. 26:2003;1211-1215
15. Kim D.J., Lee M.S., Kim K.W., Lee M.K. Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus. Metabolism. 50:2001;590-593
16. National Diabetes Data Group, Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance, Diabetes 28 (1979) 1039-1057.
17. Taniguchi A., Fukushima M., Sakai M., et al. Remnant-like particle cholesterol, triglycerides, and insulin resistance in nonobese Japanese type 2 diabetic patients. Diabetes Care. 23:2000;1766-1769
18. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:1985;412-419
19. Bonora E., Saggiani F., Targher G., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 23:2000;57-63
20. Fukushima M., Taniguchi A., Sakai M., et al. Homeostasis model assessment as a clinical index of insulin resistance. Comparison with the minimal model analysis. Diabetes Care. 22:1999;1911-1912
21. American Diabetes Association: Diabetic Nephropathy (Position Statement), Diabetes Care 25 (Suppl. 1) (2002) S85-S89.
22. Chaiken R.L., Khowaja R., Bard M M., Echkert-Morton M., Banerji M.A., Lebovitz H.E. Utility of untimed urinary albumin measurement in assessing albuminuria in black NIDDM subjects. Diabetes Care. 20:1997;709-713
23. N.J. Norusis, SPSS Regression Models 10.0, SPSS Inc., Chicago, IL, 1999, pp. 45-47.
24. Guidelines Subcommittee, 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension, J. Hypertens 17 (1999) 151-183.
25. Keane F.K. The role of lipids in renal disease: future challenges. Kidney Int. 57(Suppl. 75):2000;S27-S31
26. Arcaro G., Cretti A., Balzano S., et al. Insulin causes endothelial dysfuntion in humans: sites and mechanisms. Circulation. 15:2002;576-582
27. Ritz E. Nephropathy in type 2 diabetes. J. Inter. Med. 245:1999;111-126
28. Stuhlinger M.C., Abbasi F., Chu J.W., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 287:2002;1420-1426
29. Hotamisligil G.S., Arner P., Cargo J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 95:1995;2409-2415
30. Cine S.B., Pollak E.S., Buck C.A., et al. Endothelial cell in physiology and in the pathophysiology of vascular disorders. Blood. 91:1998;3527-3561
31. Goligorsky M.S., Chen J., Brodsky S. Endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension. 37:2001;744-748
32. Baron A.D., Tarshoby M., Hook G., et al. Interaction between insulin sensitivity and muscle perfusion on glucose uptake in human skeletal muscle: evidence for capillary recruitment. Diabetes. 49:2000;768-774